PM-477 

First-in-class ε²Lysin

Medical need:

Bacterial vaginosis

High efficacy,

high precision

Pathogen:

Gardnerella spp.

Patient population:

1 in 4 women (aged 15-49) p.a. globally

Recurrence:

60% within 6 months

Current standard-of-care:

Broad-spectrum antibiotics (acute) and long-term suppressive antibiotics (chronic)

Cleaving domain

PM-477 has a cleaving domain. After it binds to the cell wall, it lyses it. The cell bursts and the bacteria die.

Binding domain

PM-477 has a Gardnerella specific binding domain. It only binds to the cell wall of Gardnerella bacteria. It is specific.

PM-477

Target pathogen: Gardnerella spp.

Indication: Bacterial vaginosis

Discovery

Lead optimization

Pre-clinical

Phase I

Phase II

pm-477 thumbnail

Read our Publication 

The first publication detailing PM-477 is now available.  

Scientific Advisory Board

Prof. Dr. med. Werner Mendling

Prof. Dr. Christina Muzny

Dr. Gregory Resch

Prof. Dr. Jane Schwebke

Prof. Dr. Jack Sobel

PD Dr. Alexander Swidsinski

Prof. Dr. Mario Vaneechoutte

Prof. Dr. med. Hans Verstraelen

PhagoMed Biopharma GmbH

Leberstraße 20

1110 Vienna

Austria

contact@phagomed.com

Imprint & Privacy Policy